NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad, R.I.; Nasr, C.; Bischoff, L.; Busaidy, N.L.; Byrd, D.; Callender, G.; Dickson, P.; Duh, Q.Y.; Ehya, H.; Goldner, W.; Haymart, M.; Hoh, C.; Hunt, J.P.; Iagaru, A.; Kandeel, F.; Kopp, P.; Lamonica, D.M.; McIver, B.; Raeburn, C.D.; Ridge, J.A.; Ringel, M.D.; Scheri, R.P.; Shah, J.P.; Sippel, R.; Smallridge, R.C.; Sturgeon, C.; Wang, T.N.; Wirth, L.J.; Wong, R.J.; Johnson-Chilla, A.; Hoffmann, K.G.; Gurski, L.A.

doi:10.6004/jnccn.2018.0089

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Details

Request a copy

Serval ID

serval:BIB_B5E270CD6FAF

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Journal

Journal of the National Comprehensive Cancer Network

Author(s)

Haddad R.I., Nasr C., Bischoff L., Busaidy N.L., Byrd D., Callender G., Dickson P., Duh Q.Y., Ehya H., Goldner W., Haymart M., Hoh C., Hunt J.P., Iagaru A., Kandeel F., Kopp P., Lamonica D.M., McIver B., Raeburn C.D., Ridge J.A., Ringel M.D., Scheri R.P., Shah J.P., Sippel R., Smallridge R.C., Sturgeon C., Wang T.N., Wirth L.J., Wong R.J., Johnson-Chilla A., Hoffmann K.G., Gurski L.A.

ISSN

1540-1413 (Electronic)

ISSN-L

1540-1405

Publication state

Published

Issued date

12/2018

Peer-reviewed

Oui

Volume

Number

Pages

1429-1440

Language

english

Notes

Publication types: Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.

Keywords

Antineoplastic Combined Chemotherapy Protocols/standards, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Biomarkers, Tumor/genetics, Biomarkers, Tumor/metabolism, Carcinoma/diagnosis, Carcinoma/mortality, Carcinoma/pathology, Carcinoma/therapy, Clinical Trials as Topic, Humans, Image-Guided Biopsy/methods, Image-Guided Biopsy/standards, Medical Oncology/standards, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors/standards, Protein Kinase Inhibitors/therapeutic use, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Proto-Oncogene Proteins B-raf/genetics, Societies, Medical/standards, Thyroid Gland/diagnostic imaging, Thyroid Gland/pathology, Thyroid Gland/surgery, Thyroid Neoplasms/diagnosis, Thyroid Neoplasms/genetics, Thyroid Neoplasms/pathology, Thyroid Neoplasms/therapy, Thyroidectomy/methods, Thyroidectomy/standards, Treatment Outcome, United States

OAI-PMH

oai:serval.unil.ch:BIB_B5E270CD6FAF

DOI

10.6004/jnccn.2018.0089

Pubmed

30545990

Web of science

000453034100006

Open Access

Yes

Create date

16/12/2020 22:51